Assessment of KAN-101 in Celiac Disease (ACeD)

Phase 1 Completed 41 enrolled Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA

RandomizedSequentialDouble-blindTreatment

Summary

A safety study of KAN-101 in patients with celiac disease. The study has two parts: 1. Part A - first in human study in which patients receive a single dose of KAN-101 2. Part B - patients will receive three doses of either KAN-101 or placebo

Timeline

Start: 2020-01-21
Primary completion: 2021-10-08
Completion: 2021-10-08

Publications

Murray JA, Wassaf D, Dunn K, Arora S, Winkle P, Stacey H, Cooper S, Goldstein KE, Manchanda R, Kontos S, Grebe KM. Safety and tolerability of KAN-101, a liver-targeted immune tolerance therapy, in patients with coeliac disease (ACeD): a phase 1 trial. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):735-747. doi: 10.1016/S2468-1253(23)00107-3. Epub 2023 Jun 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	KAN-101	Peptide	0.15 mg/kg	Intravenous
Subject	KAN-101	Peptide	0.3 mg/kg	Intravenous
Subject	KAN-101	Peptide	0.6 mg/kg	Intravenous
Subject	KAN-101	Peptide	1.2 mg/kg	Intravenous
Subject	KAN-101	Peptide	1.5 mg/kg	Intravenous

Assessment of KAN-101 in Celiac Disease (ACeD)

Summary

Timeline

Publications

Drugs

Indications